AbbVie raises sales outlook of Skyrizi, Rinvoq to USD 17.5 billion in 2025
The two drugs Skyrizi and Rinvoq are part of AbbVie's long term growth strategy to offset Humira's loss of exclusivity.
New Delhi: AbbVie Inc on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira.
The company's previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion.
AbbVie also expects peak sales of the drugs to exceed $21 billion in 2027. The two drugs are part of the company's long-term growth strategy to offset Humira's loss of exclusivity.
The drug maker has been in contract negotiations with insurers and pharmacy benefit managers for Humira for this year, and said in October that pricing of its rivals would determine the drug's sales this year.
Next Story
